KIF5B-MET Gene Rearrangement with Robust Antitumor Activity in Response to Crizotinib in Lung Adenocarcinoma

被引：39

作者：

Cho, Jang Ho ^{[1
]}

Ku, Bo Mi ^{[2
]}

Sun, Jong-Mu ^{[1
]}

Lee, Se-Hoon ^{[1
]}

Ahn, Jin Seok ^{[1
]}

Park, Keunchil ^{[1
]}

Ahn, Myung-Ju ^{[1
]}

机构：

[1] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Hematol Oncol,Dept Med, 81 Irwon Ro, Seoul 135710, South Korea

[2] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Samsung Biomed Res Inst, Seoul, South Korea

来源：

JOURNAL OF THORACIC ONCOLOGY | 2018年 / 13卷 / 03期

关键词：

MET; ACTIVATION; CANCER;

D O I：

10.1016/j.jtho.2017.10.014

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

[No abstract available]

引用

页码：E29 / E31

页数：3

共 7 条

[1] Responses to Crizotinib Can Occur in High-Level MET-Amplified Non-Small Cell Lung Cancer Independent of MET Exon 14 Alterations [J].

Caparica, Rafael ;

Yen, Cheng Tzu ;

Coudry, Renata ;

Ignatius, Sai-Hong ;

Varella-Garcia, Marileila ;

Camidge, D. Ross ;

de Castro, Gilberto, Jr. .

JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) :141-144

[2] Activation of MET via Diverse Exon 14 Splicing Alterations Occurs in Multiple Tumor Types and Confers Clinical Sensitivity to MET Inhibitors [J].

Frampton, Garrett M. ;

Ali, Siraj M. ;

Rosenzweig, Mark ;

Chmielecki, Juliann ;

Lu, Xinyuan ;

Bauer, Todd M. ;

Akimov, Mikhail ;

Bufill, Jose A. ;

Lee, Carrie ;

Jentz, David ;

Hoover, Rick ;

Ou, Sai-Hong Ignatius ;

Salgia, Ravi ;

Brennan, Tim ;

Chalmers, Zachary R. ;

Jaeger, Savina ;

Huang, Alan ;

Elvin, Julia A. ;

Erlich, Rachel ;

Fichtenholtz, Alex ;

Gowen, Kyle A. ;

Greenbowe, Joel ;

Johnson, Adrienne ;

Khaira, Depinder ;

McMahon, Caitlin ;

Sanford, Eric M. ;

Roels, Steven ;

White, Jared ;

Greshock, Joel ;

Schlegel, Robert ;

Lipson, Doron ;

Yelensky, Roman ;

Morosini, Deborah ;

Ross, Jeffrey S. ;

Collisson, Eric ;

Peters, Malte ;

Stephens, Philip J. ;

Miller, Vincent A. .

CANCER DISCOVERY, 2015, 5 (08) :850-859

[3] Response to Crizotinib in a Patient With Lung Adenocarcinoma Harboring a MET Splice Site Mutation [J].

Jenkins, Russell W. ;

Oxnard, Geoffrey R. ;

Elkin, Sheryl ;

Sullivan, E. Kelly ;

Carter, Jennifer L. ;

Barbie, David A. .

CLINICAL LUNG CANCER, 2015, 16 (05) :E101-E104

[4] Activation of MET by Gene Amplification or by Splice Mutations Deleting the Juxtamembrane Domain in Primary Resected Lung Cancers [J].

Onozato, Ryoichi ;

Kosaka, Takayuki ;

Kuwano, Hiroyuki ;

Sekido, Yoshitaka ;

Yatabe, Yasushi ;

Mitsudomi, Tetsuya .

JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (01) :5-11

[5] MET exon 14 juxtamembrane splicing mutations: clinical and therapeutical perspectives for cancer therapy [J].

Pilotto, Sara ;

Gkountakos, Anastasios ;

Carbognin, Luisa ;

Scarpa, Aldo ;

Tortora, Giampaolo ;

Bria, Emilio .

ANNALS OF TRANSLATIONAL MEDICINE, 2017, 5 (01)

[6] Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors [J].

Sequist, Lecia V. ;

Waltman, Belinda A. ;

Dias-Santagata, Dora ;

Digumarthy, Subba ;

Turke, Alexa B. ;

Fidias, Panos ;

Bergethon, Kristin ;

Shaw, Alice T. ;

Gettinger, Scott ;

Cosper, Arjola K. ;

Akhavanfard, Sara ;

Heist, Rebecca S. ;

Temel, Jennifer ;

Christensen, James G. ;

Wain, John C. ;

Lynch, Thomas J. ;

Vernovsky, Kathy ;

Mark, Eugene J. ;

Lanuti, Michael ;

Iafrate, A. John ;

Mino-Kenudson, Mari ;

Engelman, Jeffrey A. .

SCIENCE TRANSLATIONAL MEDICINE, 2011, 3 (75)

[7] The landscape of kinase fusions in cancer [J].

Stransky, Nicolas ;

Cerami, Ethan ;

Schalm, Stefanie ;

Kim, Joseph L. ;

Lengauer, Christoph .

NATURE COMMUNICATIONS, 2014, 5

← 1 →